Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG-PLUS trial of BCG with alendronic acid or MMR to enhance trained immunity
NL-OMON27545Not yet recruiting
- Sponsor
- Radboudumc
- Start
- May 2020
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised trial of bcg vaccine, alendronate and measles, mumps, and rubella vaccine in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Radboudumc. Planned start May 2020; status: not yet recruiting.
02
Drugs
bcg vaccinealendronatemeasles, mumps, and rubella vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON27545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27545.